Navigation Links
Statement by Teva Pharmaceuticals on Eshoo-Barton Bill
Date:3/17/2009

NORTH WALES, Pa., March 17 /PRNewswire-USNewswire/ -- Teva Pharmaceuticals USA, the leading generic pharmaceutical company, today released the following statement by Debra Barrett, Senior Vice President of Government Affairs on the introduction of a biogenerics bill by Representatives Anna Eshoo and Joe Barton:

"In this year of healthcare reform, consumers should rightfully demand better access to affordable medicines. The legislation re-introduced in the House today is clearly written to protect brand-name drugs and their innovator's government-granted monopoly at the expense of access and innovation. This bill will dampen innovation and deny Americans access to more affordable healthcare.

"Congress took a bold step in 1984 when it passed Hatch-Waxman - an effort that led to the greatest explosion of innovative medicines in history - while creating a pathway for more affordable alternatives. We hope that our policymakers will enact legislation that puts the interests of patients above the guarantee of excessive monopoly."

About Teva

Teva USA is a wholly-owned subsidiary of Teva Pharmaceutical Industries Ltd., one of the largest generic pharmaceutical companies in the world and among the top 20 pharmaceutical companies. For more information, please visit www.tevausa.com or www.tevadc.com.

    Media Contact: Denise Bradley
    Phone: (215) 591-8974
    E-mail: Denise.Bradley@tevausa.com


'/>"/>
SOURCE Teva Pharmaceuticals USA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Statement by Shelby Knox on the Introduction of the REAL Act
2. Grocery Manufacturers Association Statement Regarding President Obamas Nomination of FDA Commissioner
3. GPhA Statement on Nomination of Dr. Margaret Hamburg as Commissioner and Dr. Joshua Sharfstein as Deputy Commissioner of FDA
4. AJWS Asks International Community to Demand Reinstatement of International Aid Groups Into Sudan
5. Insmed Announces FDA Issues Statement Regarding Position on Allowing Patients With ALS Access to IPLEX(TM) Under an IND
6. Pelosi Statement on President Obamas Executive Order on Stem Cell Research
7. AHIP Statement on White House Health Care Summit
8. Change to Win Statement on White House Health Care Forum
9. Statement by Bruce Bodaken, Chairman & CEO, Blue Shield of California, Regarding President Obamas Healthcare Summit
10. AAJ Statement on Supreme Court Decision in Favor of Diana Levine
11. NJLRA Statement on Todays U.S. Supreme Courts Decision in Wyeth v. Levine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... provider of comprehensive treatment for eating disorders, is opening a brand new child ... provide individuals ages 8-17 and their families with even more specialized eating disorder ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... of Mehling Orthopedics and chief medical officer of Blue Horizon International (BHI), Brian ... Regeneration. The conference was held during May 5-6, 2016 in Chicago, IL, USA. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer of the ... more than humbled by customer demand over the Mother’s Day Weekend promotion. So much ... that Bunion Bootie has completely replenished its inventory levels, it hopes to continue its ...
(Date:5/26/2016)... ... 26, 2016 , ... The introduction of our professional athletes coincides with the ... , “We are proud to introduce Meghan Klingenberg, defender and World Champion ... Quick, wide receiver for Los Angeles who was a second round selection in the ...
(Date:5/26/2016)... ... May 26, 2016 , ... May 2016 – Lips ... central to popular cosmetic improvement efforts. Record numbers of clients now ask about lip ... or pouty, says Kally Papantoniou, MD, of Advanced Dermatology P.C. , The ...
Breaking Medicine News(10 mins):
(Date:5/26/2016)... 26, 2016 A key trend ... the emergence of new treatments. Cardax, a development stage ... treatment. The therapy is expected to fulfil large unmet ... is conducting studies to develop new treatments for osteoarthritis. ... genes involved in osteoarthritis are being investigated, and early ...
(Date:5/26/2016)... , May 26, 2016   Change ... and analytics, network solutions and technology-enabled services ... it entered into a strategic channel partnership ... outpatient software solutions and revenue cycle management ... hospitals and rehabilitation clinics to optimize revenue, ...
(Date:5/25/2016)... PARIS , May 25,2016 ... with the near-infrared Cellvizio platform for urological and ... MKEA, OTCQX: MKEAY) inventor of Cellvizio®, the multidisciplinary ... important regulatory milestone in the US with the ... Food and Drug Administration (FDA). This new FDA ...
Breaking Medicine Technology: